

# State of Illinois Drugs and Therapeutics Advisory Board

## Minutes for Jan 09, 2025, Meeting

- I. Dr. Mahesh Patel opened the meeting at 8:33am.
- II. Roll Call was taken.
- III. No announcements
- IV. No conflicts of interest.
- V. The October 10, 2024, meeting minutes were unanimously approved.

Motion: To approve the October 10<sup>th</sup> D&T meeting minutes

Second: Dr. Nicole Florence

Motion passed without dissent.

- VI. PDL Drug Appeals- None
- VII. New Drug Appeals-Dr. Jen Phillips

### A. Zurzuvae (Zuranolone)

Presented by: Jen Phillips, PharmD

#### **Presented Material Highlights:**

- Indication: Post Partum Depression
- First oral medication indicated for the treatment of postpartum depression.
- Zurzuvae can cause CNS depressant effects.
- Concerns about Zurzuvae during breastfeeding.
- ACOG guidelines note Zurzuvae is recommended as a consideration in women for postpartum depression and it can be used alone or in combination with oral antidepressant therapy.

#### **Discussion Highlights:**

- Dr. Alicia Wesley spoke on how Zurzuvae has worked for her patients.
- Updated data has shown that Zurzuvae should not be expected to result in any adverse effects in infants receiving breastmilk.

- Dr. Ashley Wesley discussed about the use of Zurzuvae along with other antidepressant medications.
- Discussion about if Zurzuvae has a prior authorization, what would the prior authorization criteria look like.
- If Zurzuvae is moved to no prior authorization required, the department shall conduct audits on physicians to make sure the medication is being prescribed for the appropriate indication per the guidelines.

Motion: Dr. Vergara-Rodriguez moved to move Zurzuvae from non-preferred to preferred.

Second: Dr. Mahesh Patel

Motion passed without dissent.

## VIII. Class Reviews

### a. Topic: HIV Drug Class Review

Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- Several treatment classes
- Guidelines note regimens should be individualized.
- Inverse, didanosine, and stavudine are no longer available and are no longer recommended per the guidelines.
- Maraviroc, per the guidelines, has a role in patients who have failed other therapeutic regimens and was recommended by the AIDS foundation as an important treatment option.

Discussion Highlights:

- All forms of Maraviroc should be made preferred for pediatrics and patients with difficulty swallowing.

Motion: Dr. Vergara-Rodriguez moved that all forms of Maraviroc be made preferred.

Second: Dr. Nicole Florence

Motion passed without dissent.

Motion: Dr. Vegara-Rodriguez moved that Rukobia be made preferred.

Second: Dr. Nicole Florence

Motion passed without dissent.

Motion: Dr. Vegara-Rodriguez moved that invirase, didanosine, and stavudine be made non-preferred.

Second: Dr. Paul Berkowitz

Motion passed without dissent.

#### IX. New Drug Initial Reviews

##### A. Product: Miplyffa (arimoclomol)

Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- Indicated for treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in combination with miglustat.
- Taken three times daily and no contraindications.
- Not recommended during pregnancy and no information on breastfeeding.
- Indicated for ages 2 and older.

Discussion Highlights

- Miplyffa has been shown to slow or stop disease progression.
- Relatively new medication, low utilization, and low overall prevalence of this disease.

Motion: Dr. Mahesh Patel moved to leave Miplyffa as non-preferred.

Second: Garry Moreland

Motion passed without dissent.

##### B. Product: Ycanth (Cantharidin Soln. 0.7%)

Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- Indicated for Molluscum Contagiosum.

- Medication highly recommended in patients that are immunocompromised or if sexually transmitted.
- Administered topically every 3 weeks for patients two years of age and older.
- Must be administered in the physician's office.

Discussion Highlights:

- Can't be administered at home and must be administered in the dermatologist's office.
- Other alternative options available that are preferred.

Motion: Garry Moreland moved to leave non-preferred.

Second: Dr. Nicole Florence

Motion passed with no dissent.

C. Product: Orladeyo

Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- Background information on the treatment and prevention of hereditary angioedema (HAE).
- Once daily medication indicated for prevention of HAE attacks.
- This is an oral agent used for acute and breakthrough treatment.

Discussion Highlights:

- Decision to table this medication to hear public comment before voting on this medication.

Motion: Garry Moreland moved to table this discussion until next meeting so we can hear public comments.

Second: Dr. Mahesh Patel

Motion passed without dissent.

D. Product: Yorvipath (Palopegteriparatide)

Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- Disease state background, clinical information and guidelines recommendations given regarding hypoparathyroidism.

- Once daily medication indicated for the treatment of hyperparathyroidism in adults.
- This is an oral agent used for acute and breakthrough treatment.

Discussion Highlights:

- Theresa \_\_\_\_\_ with medical affairs at Ascenda Pharma gave a 3 min public comment regarding the medication.
- Discussion of pros and cons of palopegteriparatide vs teriparatide.
- Medication recently became available commercially.

Motion: Dr. Nicole Florence moved to leave Yorvipath non-preferred

Second: Dr. Janet Albers

Motion passed without dissent.

E. Product: Livdelzi (Seladelpar)

Presented by: Jen Phillips, PharmD

Presented Material Highlights:

- Drug summary and review of clinical information and guidelines recommendations.
- Indicated for primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA or as monotherapy if unable to tolerate UDCA.
- This is an oral agent used for acute and breakthrough treatment.
- One capsule daily and needs to be separated from bile acid sequestrants 4 hours before or 4 hours after bile acid sequestrants.

Discussion Highlights:

- Chase Williams, a medical liaison with Gilead, spoke regarding Livdelzi.
- Discussion on the prevalence of PBC.

Motion: Dr. Pamela Vergara-Rodriguez leave to leave Livdelzi non-preferred.

Second: Dr. Nicole Florence

Motion passed without dissent.

X. Public Testimony-None

XI. Speaker List

Speaker	Product	Organization
Chase Williams	HIV products	Gilead

XII. Old and New Business

- January 9, 2025
- April 10, 2025
- July 10, 2025
- October 9, 2025

XIII. Future Agenda Preview

XIV. HFS Update- None

XV. Department Update-Jose Jimenez, BPAS Bureau Chief

- Thanks to board members for their commitments.

XVI. Adjournment-Dr. Patel adjured the meeting at 10:47 am.

**Panelist List**

1. Alyssa Stephenson
2. Sheri Dolan
3. **Arvind Goyal**
4. Heather Freeman
5. **Janet Albers**
6. Jennifer Dewitt
7. Jose Jimenez
8. **Garry Moreland**
9. Claudia Colombo
10. **Maurice Shaw**
11. **Nicole Florence**

12. **Pamela Vergara-Rodriguez**
13. Mary Moody
14. **Mahesh Patel**
15. Steve Sproat
16. **Thomas Dorn**
17. Jen Phillips
18. Brianna Hudak
19. Melissa Davis
20. **Paul Berkowitz**

Attendee List

7. Chase Williams